A top 10 pharma company wanted to conduct a PICO simulation for a key product scheduled to undergo EU Joint Clinical Assessment (JCA) evaluation in 2025.
The simulation aimed to test our client’s current access and evidence strategy as well as to identify gaps and ensure that it was aligned with the expected EU JCA assessment scope.
It was important to implement a structured PICO prediction and prioritization process tailored to the company’s needs.
First, we created a comprehensive PICO universe for the product. Then we surveyed 10 affiliates on the different PICO scenarios likely to be requested by local payers and evaluated the strategic importance of each to prioritize them. Our team used the consolidated survey results to assess PICOs based on asset strategy, affiliate feedback, ability to generate favorable data, and franchise considerations.
A multi-country workshop was also organized to discuss these results and to align on the final prioritization of PICOs.
Finally, we evaluated current evidence plans and identified the plans’ strengths and opportunities for improvement, ensuring support for the prioritized PICOs.
Our client was able to significantly elevate awareness within affiliates about the PICO scoping process and the likely prioritization at the EU-level.
The company realized the need for additional localized data to support high-priority PICOs in certain key markets that may not be supported by the global strategy. Additionally, we helped make strategic adjustments to its access and evidence development strategy to help it navigate the 2025 EU JCA process confidently.
お問い合わせ
サイモン・クチャーのエキスパートがいつでもご相談に応じます。お気軽にお問い合わせください。